|
Post by mnkdfann on Oct 2, 2021 21:32:11 GMT -5
So, I believe the FDA decision is anticipated by the end of the month.
What are expectations for the MNKD share price, in the cases of both approval and non-approval?
I wonder if an options straddle would be a good strategy about now.
I see the November 4.50 call and put each last traded at 0.55 and 0.65, respectively.
|
|
|
Post by mnkdfann on Oct 1, 2021 8:55:32 GMT -5
It seems ever so likely that United purchased the building. Wouldn't the purchase appear in UTHR's third quarter report? The agreement clearly states who the purchaser is, and it wasn't UTHR. See the agreement, or some of the posts above. To reiterate, this was the purchaser: cmpreit.com/about
|
|
|
Post by mnkdfann on Sept 29, 2021 21:16:30 GMT -5
The 9.5MM annually, come at 190 MM for 20 years. Actually, the interest could be like 0.00% annually for 30 years if they write off the property at the end of the 30 years. At the end, with all me money they save in tax deductions, repairs and the return they could make with this 100MM in 30 years, this building will be peanuts to them by that time and they can and probably will build a bigger and more efficient facility in a few years. All this contingent on investing the money smartly and things working out with Afrezza and most importantly the rest of the molecules they are looking at now and in the future. This is a big if, but 'if' it does, this will prove to be a very good transaction. IMHO Those aren't the numbers in the agreement, though. Rent is never as low as $9.5 million after the first year. It increases annually thereafter. The total rent paid over your 20 years is more like over $245 million at the end (and ignoring time value). Personally, I don't see how you come out ahead by taking $102.5 million now and paying that amount of interest. It certainly does not translate into a low rate, anyway. Also, as far as I can see, it is not their building to write off at the end unless they take the option in the agreement to buy it back for the greater of $102.5 million or the fair market value (again, whichever is greater). Why would they buy it back for $102.5 million or more, to write it off for that or less? And, I don't know that they will save money on repairs. The agreement says Mannkind is still responsible for operating expenses, which includes general repairs and maintenance. Hopefully, the deal does somehow work out well in the end, but I don't think your defence of it stacks up given the factual details in the posted agreement. I think it is far from a sweetheart deal for Mannkind, and the terms are not great.
|
|
|
Post by mnkdfann on Sept 29, 2021 19:56:45 GMT -5
If you calculate cost of money, that is like a loan at around 3% annually. Considering the inflation at over 3% and likely increasing drastically with these monkeys in power, and accounting for the benefits they can get out of these funds in the immediate term, this is a very good deal in my mind. I haven't done the exact calculation, but I think the numbers make it quite a bit higher than 3%.
|
|
|
Post by mnkdfann on Sept 29, 2021 19:01:54 GMT -5
The best time to raise money is when you don’t need it. You get the best terms that way.If those were the best terms, I'd hate to see the worse ones. What I mean, is that for $102.5 million, Mannkind is paying a pretty hefty rent that is set to increase steadily (increases of 2.5% and 3.5% annually in future years) to over 10% per annum (i.e. over 10% of 102.5 million) very quickly. On top of that, the agreement also says that "MannKind will also be responsible for payment of operating expenses, property taxes and insurance for the Real Property." Mannkind really can't borrow money for less than that?
|
|
|
Post by mnkdfann on Sept 29, 2021 18:54:28 GMT -5
The interesting question is who is the purchaser? Let the conspiracy theories begin! 😁 It says right there in the document that was posted. 1 Casper, LLC, an affiliate of Creative Manufacturing Properties, Inc. The latter acquires these properties, then tries to find tenants. cmpreit.comcmpreit.com/solutions
|
|
|
Post by mnkdfann on Sept 23, 2021 23:35:42 GMT -5
How are they ever going to buy the stock without moving it? I think it was mnkdfann on some volume thread, when MNKD broke, $2.25, the measured move was $7.50, and mnkdfann wanted to know what was going to take price to $7.50. If it was me, I have no such recollection. But, then again, I forget a lot of minutia.
|
|
|
Post by mnkdfann on Sept 17, 2021 15:05:53 GMT -5
Gold veins I think it was Veins have worn down to threads, is what I thought peppy was going for. Or I may be giving her sarcastic wit too much credit.
|
|
|
Post by mnkdfann on Sept 1, 2021 14:45:07 GMT -5
According to Wikipedia, UTHR has a workforce of 950 people and Mannkind's is well over 200.
I'm no great management expert, but why would UTHR want to take on so much? Most of it would be dead wood so far as UTHR's needs go.
My understanding is that lots of big Pharma companies depend on other suppliers to manufacture what they need.
UTHR indeed HAS bought out companies, but I think far more often it just licenses or partners to get what it needs.
|
|
|
Post by mnkdfann on Aug 25, 2021 15:43:47 GMT -5
Hate to be a critic, but here I go ... On the edge or verge of greatness, I can see. Eclipse of greatness? Not really sure how to parse that. The dictionary meaning of eclipse would appear to make that a bad thing. www.merriam-webster.com/dictionary/eclipseEclipse: obscure, darken, falling into obscurity or declinealrighty then. Look at NVAX, 1 for 20 in 2019 The split for NVAX took place on May 10, 2019. This was a 1 for 20 reverse split, meaning for each 20 shares of NVAX owned pre-split, the shareholder now owned ... Now with a market cap of Market Cap 17.741B and an EPS (TTM) -13.84. The vaccine isn't even on the market. SMH I'm not sure what you are saying / why you are quoting my post. I was only suggesting that the word 'eclipse' is actually the opposite of what mango really meant. Of course, it is entirely possible I am mistaken (which is why I included a dictionary link, so people can look it up for themselves). Not a big deal, I was just throwing it out there as an editorial suggestion in case mango wants to republish his essay / commentary elsewhere.
|
|
|
Post by mnkdfann on Aug 25, 2021 15:07:41 GMT -5
Hate to be a critic, but here I go ... On the edge or verge of greatness, I can see. Eclipse of greatness? Not really sure how to parse that. The dictionary meaning of eclipse would appear to make that a bad thing. www.merriam-webster.com/dictionary/eclipseEclipse: obscure, darken, falling into obscurity or decline
|
|
|
Post by mnkdfann on Aug 16, 2021 14:20:10 GMT -5
The $105M is a good point. Then add in the manufacturing facility cost and UTHR is in up to their eyeballs. Which manufacturing facility are you talking about? Isn't this one still owned by Mannkind? The 8k says: "Under the terms of the Supply Agreement, MannKind will be responsible for manufacturing Products in its Danbury, Conn. facility"
|
|
|
Post by mnkdfann on Aug 12, 2021 0:25:54 GMT -5
|
|
|
Post by mnkdfann on Aug 11, 2021 20:35:38 GMT -5
You need to watch more horror movies and build up a tolerance, so you are not so easily scared.
|
|
|
Post by mnkdfann on Aug 11, 2021 20:33:03 GMT -5
In response, United Therapeutics sued Liquidia for infringing two patents, U.S. Patent Nos. 9,604,901 and 9,593,066, and later added a third patent, U.S. Patent No. 10,716,793, in the United States District Court for the District of Delaware.
That may be what UTHR claims, and maybe what UTHR claims is in fact true, but I'm willing to bet Liquidia will have a different take on things. And who knows what a court will decide.
|
|